非维生素K口服抗凝药与醋硝香豆素预防卒中的临床结局
基于西班牙瓦伦西亚地区电子健康记录的人群回顾性队列研究纳入41,560例新使用口服抗凝药的非瓣膜性房颤患者,采用逆概率治疗加权Cox分析比较NOAC与醋硝香豆素的有效性和安全性。总体上未发现死亡、缺血性卒中或任何胃肠道出血风险差异,但达比加群和利伐沙班较醋硝香豆素降低颅内出血风险。
要点
- 达比加群较醋硝香豆素降低颅内出血风险(HR 0.34,95%CI 0.20-0.56)。
- 利伐沙班较醋硝香豆素降低颅内出血风险(HR 0.55,95%CI 0.35-0.85)。
- ≥75岁且CHA2DS2-VASC评分≥2者中阿哌沙班缺血性卒中风险更高。
核心结论
- 总体而言NOAC与醋硝香豆素在死亡、缺血性卒中和任何胃肠道出血风险上无差异。
- 达比加群和利伐沙班较醋硝香豆素颅内出血风险更低。
- 特定NOAC在高危亚组中可能劣效的发现需进一步研究。
研究设计与样本
- 基于西班牙瓦伦西亚地区多个电子健康记录链接的人群回顾性队列研究。
- 采用逆概率治疗加权Cox分析控制适应症偏倚,并进行了多项敏感性分析。
主要发现
- 未发现死亡、缺血性卒中或任何胃肠道出血的风险差异。
- 达比加群较醋硝香豆素颅内出血风险降低(HR 0.34,95%CI 0.20-0.56)。
- 利伐沙班较醋硝香豆素颅内出血风险降低(HR 0.55,95%CI 0.35-0.85)。
- 亚组分析中阿哌沙班在≥75岁且CHA2DS2-VASC评分≥2者中缺血性卒中风险更高。
临床怎么用
- 在非瓣膜性房颤卒中预防中,达比加群和利伐沙班可作为降低颅内出血风险的抗凝选择参考。
- 对≥75岁且CHA2DS2-VASC评分≥2者使用阿哌沙班时应关注缺血性卒中风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Acenocoumarol is a vitamin-K antagonist (VKA) primarily used in certain countries (e.g. India, Netherlands, Spain). The half-life of acenocoumarol is similar to that of non-VKA oral anticoagulants (NOAC), unlike warfarin, and this could affect comparative effectiveness and safety (CES). However, data on CES for NOAC come almost exclusively from studies using warfarin as the comparator. We aimed to assess outcomes of NOAC and acenocoumarol in people with non-valvular atrial fibrillation (NVAF) in real-world clinical practice. METHODS: This is a population-based retrospective cohort study. All new users of oral anticoagulants from November 2011 to December 2015 with NVAF were included (n = 41,560). Data were obtained by linking several health electronic records of the Valencia region, Spain. Incidence rates were estimated. We used the inverse probability of treatment weighted Cox analysis to control for indication bias when assessing the risk of effectiveness and safety outcomes for each NOAC compared with acenocoumarol. Several sensitivity analyses were performed. RESULTS: We did not find differences in the risk of mortality, ischaemic stroke or any gastrointestinal bleeding. However, we did find a decreased risk of intracranial haemorrhage for dabigatran (HR: 0.34, 95% CI 0.20-0.56) and rivaroxaban (HR: 0.55, 95% CI 0.35-0.85) as compared to acenocoumarol. In subanalyses, apixaban showed a higher risk of ischaemic stroke in high-risk persons (≥75 years and CHA2DS2-VASC score ≥ 2). CONCLUSIONS: No differences in clinical outcomes were found between NOAC and acenocoumarol overall, although dabigatran and rivaroxaban showed a lower risk of intracranial haemorrhage. Findings on the potential inferiority of specific NOAC in high-risk subgroups should be studied further.
引用
- Rodríguez-Bernal CL, Santa-Ana-Téllez Y, García-Sempere A, et al. Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A population-based propensity-weighted cohort study. Br J Clin Pharmacol. 2020. PMID: 32530052. doi:10.1111/bcp.14430
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。